Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of BNT327 (Pumitamig) + chemotherapy vs atezolizumab + chemotherapy in first-line extensive-stage small-cell lung cancer
jRCT2051250041Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in small cell lung cancer (SCLC) (5 arms), sponsored by BioNTech SE. Primary endpoint: Overall survival. Started Feb 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2051250041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250041.